Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report

INTRODUCTION: This is the fourth case reporting the administration of tocilizumab to control hyperhaemolysis. It was administered with rituximab to stop hyperhaemolysis refractory to frontline therapy. Hyperhaemolysis is a rare life-threatening subtype of delayed haemolytic transfusion reaction. Ref...

Descripción completa

Detalles Bibliográficos
Autores principales: El Afifi, Amal M., Saeed, Alia M., Fekry, Gihad H., Mostafa, Mariam A., Elmetwally, Reham A., Hamed, Inas M., Hussein, Aliaa N., Hasanien, Gomaa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911996/
https://www.ncbi.nlm.nih.gov/pubmed/36818772
http://dx.doi.org/10.1159/000524743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911996/
https://www.ncbi.nlm.nih.gov/pubmed/36818772
http://dx.doi.org/10.1159/000524743

Ejemplares similares